Research funder · United States
Alzheimer's Drug Discovery Foundation
Nonprofit organization
- Grants since 2016
- 326
- Awarded, last 5 years (where amounts are published)
- $245.1M
- Funded works, last 5 years
- 1 178
- Funded works, all time
- 2 272
Grants
2023–2026 · research · Biomarkers
Probing neuroinflammation in Alzheimer's with NLRP3 PET radiotracers
Shijun Zhang · Virginia Commonwealth University
2023–2026 · research · Diagnostics Accelerator
MAP-AD, a revolutionary Methylation Profiling approach for early diagnosis of Alzheimer’s Disease
Marta Barrachina · Admit Therapeutics S.l.
2023–2024 · research · Diagnostics Accelerator
Validation of a set of peripheral biomarkers with the potential to identify individuals at risk of developing Alzheimer's disease at the cross-section between early environmental neurotoxicity and prodromal Alzheimer's disease.
Maria Tsamou · Toxgensolutions Bv
2023–2029 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Sergi Valero · Fundacio Ace, Icna
2023–2026 · research · Diagnostics Accelerator
Clinical Validation of a Robust Blood Test Using Neuron-Derived Exosomes For Detection Of Alpha-Synuclein/TDP43 Pathologies in Patients With Alzheimer’s Disease
Erez Eitan · Neurodex
2023–2025 · research · Prevention
Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists as Pharmacotherapies to Prevent Dementia
Walter Swardfager · Sunnybrook Research Institute
2023–2026 · research · Clinical
CST-3056 - CNS Optimized α1A-AR Partial Agonist Proposal for AD and Related Diseases
Gabriel Vargas · Curasen Therapeutics Inc.
2023–2026 · research · Biomarkers
A Phase 3, Open-Label, Multicenter, Cross-sectional Study of the Diagnostic Efficacy and Safety of [18F]APN-1607 (APN-1607) Positron Emission Tomography in Patients with Progressive Supranuclear Palsy (PSP) Compared to Age-Matched Controls
Lili Zhang · Aprinoia Therapeutics Inc
2023–2026 · research · Drug Discovery
Development of AST-004 as a Treatment for Alzheimer’s Disease and Related Dementias
James Lechleiter · Astrocyte Pharmaceuticals Inc.
2023–2024 · research · Diagnostics Accelerator
Salivary neurofilament light and YKL-40 as prognostic biomarkers of cognitive decline.
Elizabeth Thomas · University of California, Irvine
2023–2026 · research · Clinical
Multiple Ascending Dose Studies to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Effects of NTRX-07 in Subjects with Early Alzheimer's disease (AD)
Tony Giordano · Neurotherapia, Inc.
2023–2024 · research · Drug Discovery
Developing PROTAC tau degrader to reduce pathological tau accumulation for the treatment of Alzheimer’s disease and related tauopathies
Lili Zhang · Aprinoia Therapeutics Inc
2023–2024 · research · Drug Discovery
Selecting lead candidate REV-ERB agonist for the treatment of FTD
Michele Cresap · Pelagos Pharmaceuticals, Inc.
2023–2027 · research · Diagnostics Accelerator
DAC - Implementation of fluid biomarkers for Accurate Diagnosis in Clinical Practice
Phyllis Ferrell · Davos Alzheimers Collaborative
2023–2026 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Karine Fauria · Barcelonaβeta
2023–2026 · research · Biomarkers
Use of an intrinsic brain activity biomarker for the earliest prediction of cognitive decline
Leslie Prichep · BrainScope (United States)
2023–2024 · research · Biomarkers
Evaluation of the Clinical Utility of α-Synuclein Seed Amplification Assay as an Aid in the Diagnosis of Dementia and Differentiation of Dementia Subtypes
Russell Lebovitz · Amprion (United States)
2023–2027 · research · Clinical
Translation Studies and Clinical Development of THN391, a Novel Anti-Fibrin Antibody for the Treatment of Dementia
Nuno Mendonca · Therini Bio
2023–2028 · research · Clinical
Nicotinamide Mononucleotide in Patients with Alzheimer's Disease
David Livingston · Metro International Biotech
2023–2024 · research · Diagnostics Accelerator
Development of a non-invasive biomarker for early detection of Alzheimer’s disease and patient stratification based on the delta-valerobetaine pathway.
Antal Szalay · Ultimate Medicine
2023–2029 · research · Clinical
Repurposing lenalidomide for early Alzheimer's treatment
Marwan Sabbagh · Dignity Health St Joseph's Hospital And Medical Center
2023–2024 · research · Diagnostics Accelerator
Validation of a novel, accessible, scalable, and affordable blood-based p-tau 217 assay for clinical use
Andreas Jeromin · Alzpath, Inc.
2023–2026 · research · Clinical
IND-Enabling Studies for a Novel Positive Allosteric Modulator of the Alpha1A-Adrenergic Receptor to Treat Alzheimer’s Disease
Dianne Perez · Cleveland Clinic
2023–2026 · research · Drug Discovery
Therapeutic neuroprotection in Alzheimer’s disease through controlling toxic astrocytes
Paul Tesar · Case Western Reserve University
2023–2026 · research · Biomarkers
Covert Cerebrovascular Disease Detected by Artificial Intelligence (C2D2AI): Pilot Investigation for Pragmatic Neuroimaging Biomarkers for Future Stroke and Dementia Risk
David Kent · Tufts Medical Center
2023–2026 · research · Prevention
Blood-based biomarkers of Alzheimer’s disease and neurodegeneration in the FINGER multidomain trial
Miia Kivipelto · Fingers Brain Health Institute
2022 · conference · Conferences/Other
Clinical Trials for Alzheimer’s Disease CTAD
Nathanaelle Touchon · Clinical Trials For Alzheimer's Disease Congress
2022–2029 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Rhoda Au · Boston University
2022–2026 · research · Drug Discovery
A brain-penetrant first-in-class drug candidate for the treatment of Alzheimer's disease
Andrew Harvey · Uniquest
2022–2024 · research · Biomarkers
Blood-Brain Barrier Imaging in Mild Cognitive Impairment and Alzheimer Disease
Jeremy Ford · Massachusetts General Hospital (p)
2022–2023 · research · Clinical
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
Anne-Marie Li-Kwai-Cheung · Wave Life Sciences (United States)
2022–2025 · research · Diagnostics Accelerator
Validation of MemoryLinc test’s blood ncRNAs for detection of early AD and monitoring its progression and for monitoring the responses of anti-amyloid therapeutic strategies on samples from participants with prodromal to mild AD and having Amyloid CSF or PET positivity (Amoneta follow on funding)
Hueseyin Firat · Amoneta Diagnostics
2022–2028 · research · Clinical
Evaluating the safety and efficacy of PDE-5 inhibitor as a treatment for early stages of Alzheimer's disease
Paul Edison · Imperial College London
2022–2024 · research · Clinical
Phase 3 trial of dopaminergic therapy in patients with Alzheimer’s disease.
Giacomo Koch · Fondazione Santa Lucia
2022–2024 · research · Drug Discovery
Repairing neurotransmission in Alzheimer's disease and related disorders by targeting caspase-2
Karen Ashe · University of Minnesota
2022–2026 · research · Clinical
Cognito Therapeutics - A novel digital therapeutic for neurodegenerative diseases
Ralph Kern · Cognito Therapeutics
2022–2024 · prize · Clinical
2022 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery: Senescence Biomarker Discovery
Miranda Orr · Wake Forest University
2022–2025 · research · Clinical
A Phase II Study to Determine the Preliminary Efficacy and Safety of Oral Edaravone (TW001) in Alzheimer Patient - Extension
Ronald Van Der Geest · Treeway B.v.
2022–2025 · research · Drug Discovery
Development of small molecule inhibitors of a microglia receptor as treatments for Alzheimer’s disease
Michael Parker · St Vincents Institute of Medical Research
2022–2023 · research · Clinical
Late-stage development of a PIKFYVE antisense oligonucleotide treatment for FTD
Peter Sazani · Acurastem Incorporated